Roberto Iacovelli European Association of Urology (EAU) EAU Edu Platform UROONCO OncoAlert OncoDaily UroFocus Kidney Cancer Riccardo Campi Thank you Roberto for your great contribution to the advanced RCC session! It was a pleasure having you in Seville!

Very pleased to have nirm as Society of Urologic Oncology speaker and panelist in the advanced #KidneyCancer session #UROonco25 in Seville. Looking forward to a growing collaboration of European Association of Urology (EAU) and Society of Urologic Oncology

Fantastic experience #UROonco25 in🔥Sevilla! Fantastic organization by Alessandro Volpe & #ESOU Board Thank you for the opportunity to speak, moderate, share knowledge & experiences, and learn from experts You work hard, but you always come back home #enriched from professional and

Simon C Yüksel Ürün Roberto Iacovelli European Association of Urology (EAU) European Urology OncoDaily OncoAlert UroFocus Alessandro Volpe Morgan Roupret Advanced Prostate Cancer Consensus Conference Declan Murphy Nick James also on @Prof-Nick-James.bsky.social Daniel E Spratt 💙alison birtle silke gillessen That's my point that we are now moved from ADT±ARPi to ARPI±ADT.

Simon C Yüksel Ürün Roberto Iacovelli tombal European Association of Urology (EAU) European Urology OncoDaily OncoAlert UroFocus Alessandro Volpe Morgan Roupret Advanced Prostate Cancer Consensus Conference Declan Murphy Nick James also on @Prof-Nick-James.bsky.social Daniel E Spratt 💙alison birtle silke gillessen I dream of a day when ADT isn’t the mainstay of treatment for metastatic prostate cancer! Horrendous side effects that are life changing. It’s been the main treatment since 1941. Surely we can do better?

Riccardo Campi Morgan Roupret European Urology Oncology Daniele Amparore Bernadett Szabados Thomas Zilli Roberto Iacovelli Laura Marandino European Association of Urology (EAU) EAU-YAU Renal Cancer Working Group Thanks for the nice words Riccardo! And thanks for your constant enthusiasm and dedication! 👏👏

STARTING NOW‼️#GUARDSymposium2025 Join us ONLINE for the GUARD Symposium🇪🇸 featuring interactive workshops where experts collaboratively discuss real-world genitourinary cancer cases. REGISTER👉 events.tacticsmd.net/guard-internat… ⭐️FREE VIRTUAL Admission for LMIC's & LATAM Colleagues⭐️

OncoAlert 🌍 Looking forward to this! Join us online for the first session on Renal Cancer — real cases, top experts, and interactive discussions. 🖥️ Free virtual access for LATAM & LMIC colleagues — don’t miss it! #GUonc #KidneyCancer #GUARDSymposium GUARD Consortium

Things that only can happen at #guardsymposium2025, to be seated nearby the greatest Roberto Iacovelli before Pedro C Barata, MD MSc FACP starts his brilliant talk about how we should treat mRCC patients after adjuvant ICI-based treatment. I can’t wait to the discussion!!!! GUARD Consortium OncoAlert

🌟 What’s next after IO–TKI in RCC? 👨‍⚕️ Presented by Roberto Iacovelli #GUARDSymposium2025 OncoAlert 📌 What happened in 1L trials? ▪️ Only 43–58% received 2L treatment ▪️ VEGFR TKIs were most used (esp. cabo) ▪️ Anti–PD(L)1 reuse: low 📌 Why cabozantinib? ▪️ Strong VEGFR2

🌟¿Qué sigue tras IO–TKI en cáncer renal? 👨‍⚕️ Presentado por Roberto Iacovelli #GUARDSymposium2025 OncoAlert 📌 ¿Qué pasó en los ensayos de 1L? ▪️ Solo 43–58% recibió 2L ▪️ TKIs anti-VEGFR fueron los más usados (especialmente cabo) ▪️ Reutilización de anti–PD(L)1: baja 📌 ¿Por qué

🌟 SBRT en tumores renales 👨‍⚕️ Dr. Abrahams Ocanto – Radiooncólogo #GUARDSymposium2025 Abrahams Ocanto OncoAlert 📌 Análisis conjunto IROCK (12 centros): ▪️ 223 pacientes ▪️ Tamaño tumoral mediano: 4 cm ▪️ Control local a 2 años: 97.8% 📌 FASTRACK II (fase II no randomizado): ▪️

Excelente mesa de cáncer renal en el GUARD International Symposium. ¡Y esto solo acaba de empezar!

A wonderful Presentation and discussion by our colleague Roberto Iacovelli 🇮🇹at #GUARDSymposium2025 on How to Treat Patients in 2nd Line after progression to TKI+IO #KidneyCancer

🌟 Adjuvant Therapy in Renal Cancer 👨‍⚕️ Presented by Javier Molina Cerrillo #GUARDSymposium2025 OncoAlert 📌 Current status: ▪️ Pembrolizumab (KN564) = approved, DFS+ but OS data immature ▪️ CheckMate 914 & PROSPER = negative ▪️ No predictive biomarkers ▪️ Ongoing: RAMPART, LITESPARK-022

DAY ONE🚨 #GUARDSymposium2025 Presenting Roberto Iacovelli 🇮🇹 on How to Treat Patients in 2nd Line after progression to TKI+IO #KidneyCancer Tom Powles Syed A Hussain Matt Galsky Andrea Necchi Félix Guerrero-Ramos Mario AlvarezMaestro Urbano Anido Javier Molina Cerrillo David Lorente Vital Hevia

Missing you all Roberto Iacovelli Enrique Grande Pedro C Barata, MD MSc FACP

🌟🟠 Powerful insights by Syed A Hussain at GUARD Consortium #GUARDSymposium2025 OncoAlert 💡 One disease, many paths in mUCl 🔹 >50% of mUC patients receive no 1L treatment 🔹 High dropout rate despite multiple available options 🔹 Key decision drivers: efficacy,

Day TWO #GUARDSymposium2025 🚨 Presentation by Syed A Hussain One line, several options: individualization of treatment in first-line metastatic #BladderCancer Tom Powles Syed A Hussain Matt Galsky Andrea Necchi Félix Guerrero-Ramos Mario AlvarezMaestro Urbano Anido

Gem/cis/durvalumab is approved in the EU for muscle invasive bladder cancer (NIAGARA study). It’s the only immune therapy study in the adjuvant or neoadjuvant setting with significant OS. ⬆️ pCR and EFS support this appr OncoAlert Annals of Oncology astrazeneca.com/media-centre/p…